SIM
ESPR

SSI Investment Management’s Esperion Therapeutics ESPR Stock Holding History

SSI Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-17,858
Closed -$283K – 399
2014
Q2 		$283K Buy
+17,858
New +$258K 0.03% 323
2014
Q1 		– Sell
-23,585
Closed -$325K – 413
2013
Q4 		$325K Buy
+23,585
New +$343K 0.03% 373

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SSI Investment Management's ESPR Position: Q3 2014 in Review

SSI Investment Management sold out of Esperion Therapeutics (ESPR) in Q3 2014, closing a stake of 17,858 shares — an estimated $283K sold.

SSI Investment Management first reported a position in ESPR in Q4 2013 and held it in 2 quarters. The position peaked at $325K in Q4 2013. 50 funds tracked by Wall St. Rank hold ESPR as of Q3 2014.

  • SSI Investment Management reported no remaining Esperion Therapeutics position as of Q3 2014 after selling out during the quarter.
  • SSI Investment Management sold 17,858 Esperion Therapeutics shares in Q3 2014, an estimated $283K.
  • SSI Investment Management first reported a position in Esperion Therapeutics in Q4 2013 and held it in 2 quarters.
  • SSI Investment Management's Esperion Therapeutics position peaked at $325K in Q4 2013.
  • 50 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2014.

Based on SSI Investment Management's 13F filing for Q3 2014, filed 12 Nov 2014.